Chairman of the Board
Øyvind Kongstun Arnesen was appointed chairman of the board in 2018.
Kongstun Arnesen is a Medical Doctor with more than ten years of clinical experience and extensive experience from the Pharmaceutical Industry holding positions as Medial Director Bristol-Myers Squibb B, Medical Director, and Head of Clinical Operations at Boehringer Ingelheim and CEO of Ultimovacs from 2012 to 2020. From 2010 to 2021 he served as member of the National Commision for Investigation of Research Misconduct.
He is Chairman of the Board in Hubro Therapeutics and works as an independent advisor to Radforsk, Canica and other investors in the life science sector.